Viscient Biosciences is a San Diego-based biotech company focused on utilizing 3D culture technology to develop drugs across a range of therapeutic areas. Founded by a combination of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is initially conducting discovery and development work in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Utilizing newly available three dimensional biology technologies, we explore biology in a previously unavailable context, leading to a better understanding of disease and an improved opportunity to impact patients.
For partnering or other inquiries, please use the Contact web form below.
Viscient is a privately funded biotechnology company and is not seeking investment at this time.